Anders Lilja | Senior Vice President Of Technical Development
Hookipa Biotech | Austria

Anders Lilja, Senior Vice President Of Technical Development, Hookipa Biotech

Anders Lilja is SVP Technical Development at HOOKIPA. He is responsible for developing HOOKIPA’s promising product candidates from research through GMP manufacturing. While at HOOKIPA, he led the development of our cytomegalovirus vaccine candidate HB-101 through the phase 1 clinical trial. Prior to joining HOOKIPA, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. He holds an MSc in chemical engineering from Chalmers University of Technology, Sweden, a PhD in Biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.


Oct 30th Day 2 @ 11:35

Progress on CMV vaccines and antibody therapies

  • Development of a CMV vaccine based on non-replicating lymphocytic choriomeningitis virus vectors
  • PhII data on a MVA based vaccine for the transplant space
  • Title TBC
last published: 19/Sep/19 13:06 GMT

back to speakers

Sign Up for Event Updates